Dr. Andrew Brohl at ASCO 2023: Abstract No. 9534
2 意见
• 07/17/23
0
0
嵌入
At ASCO 2023, Moffitt's Dr. Andrew Brohl discusses a phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant Merkel cell carcinoma and cutaneous squamous cell carcinoma.
显示更多
脸书评论
SORT BY-
热门评论
-
最新评论